Repare Therapeutics(RPTX) - 2024 Q4 - Annual Results

Form 8-K Current Report Results of Operations and Financial Condition Repare Therapeutics reported preliminary, unaudited cash, cash equivalents, and marketable securities of approximately $153 million as of December 31, 2024 Preliminary Financial Position | Metric | Value (Preliminary, Unaudited) | | :--- | :--- | | Cash, Cash Equivalents and Marketable Securities | Approx. $153 million | - The announced financial information is preliminary, unaudited, and represents a management estimate, subject to change upon completion of year-end financial closing procedures[5] - The company's independent registered public accounting firm has not audited or reviewed these preliminary results[5] Regulation FD Disclosure The company re-aligned resources to focus on Phase 1 clinical programs RP-1664 and RP-3467, extending cash runway into mid-2027 - Announced a re-alignment of resources and re-prioritization of its clinical portfolio[8] - The strategic focus will be on advancing Phase 1 clinical programs: RP-1664 and RP-3467[8] - Planned cost savings and headcount reductions are projected to extend the company's cash runway into mid-2027[8] Cautionary Note Regarding Forward-Looking Statements Forward-looking statements on business plans and cash runway are subject to risks and uncertainties, potentially causing actual results to differ - The report includes forward-looking statements regarding business plans, expected cost-savings, and the estimated cash runway[10] - These statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially[10] - Identified risks include the successful implementation of cost-cutting, the impact on business and employee retention, and potential litigation or regulatory actions[10] Financial Statements and Exhibits This section lists exhibits filed with the Form 8-K, including a press release dated January 9, 2025 Filed Exhibits | Exhibit No. | Description | | :--- | :--- | | 99.1 | Press Release dated January 9, 2025 | | 104 | Cover Page Interactive Data File |